Adoptive cellular immunotherapy uses immune cells isolated from tumor bearing patients that are grown ex vivo in the presence of interleukin-2 and administered to patients along with high doses of interleukin-2. Data from animal models suggested that lymphokine activated killer (LAK) cells have therapeutic efficacy when administered with interleukin-2. LAK cells, which are non-major histocompatibility complex restricted anti-tumor effectors, cause objective responses in a significant percentage of patients with melanoma, renal cell carcinoma, non-Hodgkin's lymphoma, and colorectal cancer. Tumor infiltrating lymphocytes are classic cytolytic T cells isolated from murine and human tumors. They are more therapeutically effective in experimental murine tumor models and have been shown to cause objective responses in 50% of a small series of patients with advanced melanoma who simultaneously receive high dose interleukin-2.
|Original language||English (US)|
|Number of pages||20|
|Journal||Immunology and Allergy Clinics of North America|
|State||Published - Jan 1 1991|
ASJC Scopus subject areas
- Immunology and Allergy